Literature DB >> 19723646

Phosphatidylinositol 3'-kinase catalytic subunit alpha gene amplification contributes to the pathogenesis of mantle cell lymphoma.

Amanda Psyrri1, Sotirios Papageorgiou, Elisavet Liakata, Andreas Scorilas, Dimitra Rontogianni, Christos K Kontos, Pinelopi Argyriou, Dimitrios Pectasides, Nikolaos Harhalakis, Vassiliki Pappa, Aggeliki Kolialexi, Christina Economopoulou, Frida Kontsioti, Eirini Maratou, George Dimitriadis, Panagiota Economopoulou, Theofanis Economopoulos.   

Abstract

PURPOSE: Activation of phosphatidylinositol 3'-kinase pathway is implicated in the pathogenesis of mantle cell lymphoma (MCL). The genetic change in phosphatidylinositol 3'-kinase catalytic subunit alpha (PIK3CA) in MCL has not been identified. EXPERIMENTAL
DESIGN: Thirty-five primary MCL cases and 2 MCL cell lines (GRANTA-519 and Rec-1) were used to investigate somatic mutation and gene copy number of PIK3CA. Gene copy number was determined using quantitative real-time PCR and fluorescence in situ hybridization. We used quantitative real-time reverse transcription-PCR to measure PIK3CA transcription levels. Phosphatase and tensin homologue deleted on chromosome 10 (PTEN) and phoshorylated AKT protein levels were analyzed using Western blotting and immunohistochemistry. Flow cytometry was used to assess apoptosis after treatment of MCL cell lines and one control cell line with LY294002, a specific inhibitor of PI3KCA.
RESULTS: Fifteen of 22 (68%) MCL cases and the MCL cell lines harbored a gain (> or =3) of PIK3CA gene copy number. In addition, cases with increased PIK3CA gene copy number had elevated PIK3CA mRNA levels. Furthermore, amplification of PIK3CA correlated with the status of AKT phosphorylation in 7 of 12 (58%) primary MCL cases. Inhibition of PIK3CA induced increased apoptosis in the MCL cell lines. PTEN protein expression was present in all 14 primary MCL cases and cell lines by Western blotting, whereas 5 of 33 (15%) cases tested by immunohistochemistry had loss of PTEN expression.
CONCLUSIONS: We conclude that a gain of gene copy number of PIK3CA is frequent genetic alteration that contributes to MCL progression. PIK3CA is a promising therapeutic target in MCL.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19723646     DOI: 10.1158/1078-0432.CCR-08-3215

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  39 in total

1.  DeltaN TP63 reactivation, epithelial phenotype maintenance, and survival in lung squamous cell carcinoma.

Authors:  Karine Pallier; Aurélie Cazes; Laila El Khattabi; Cristina Lecchi; Marine Desroches; Claire Danel; Marc Riquet; Elizabeth Fabre-Guillevin; Pierre Laurent-Puig; Hélène Blons
Journal:  Tumour Biol       Date:  2011-10-11

2.  Integrative genomic analysis implicates gain of PIK3CA at 3q26 and MYC at 8q24 in chronic lymphocytic leukemia.

Authors:  Jennifer R Brown; Megan Hanna; Bethany Tesar; Lillian Werner; Nathalie Pochet; John M Asara; Yaoyu E Wang; Paola Dal Cin; Stacey M Fernandes; Christina Thompson; Laura Macconaill; Catherine J Wu; Yves Van de Peer; Mick Correll; Aviv Regev; Donna Neuberg; Arnold S Freedman
Journal:  Clin Cancer Res       Date:  2012-05-23       Impact factor: 12.531

Review 3.  Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era.

Authors:  Patricia Pérez-Galán; Martin Dreyling; Adrian Wiestner
Journal:  Blood       Date:  2010-10-12       Impact factor: 22.113

4.  The pan phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor SAR245409 (voxtalisib/XL765) blocks survival, adhesion and proliferation of primary chronic lymphocytic leukemia cells.

Authors:  R Thijssen; J Ter Burg; G G W van Bochove; M F M de Rooij; A Kuil; M H Jansen; T W Kuijpers; J W Baars; A Virone-Oddos; M Spaargaren; C Egile; M H J van Oers; E Eldering; M J Kersten; A P Kater
Journal:  Leukemia       Date:  2015-09-04       Impact factor: 11.528

5.  Alternative Splicing Detection Tool-a novel PERL algorithm for sensitive detection of splicing events, based on next-generation sequencing data analysis.

Authors:  Panagiotis G Adamopoulos; Margarita C Theodoropoulou; Andreas Scorilas
Journal:  Ann Transl Med       Date:  2018-06

6.  Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial.

Authors:  Jennifer R Brown; Mehdi Hamadani; John Hayslip; Ann Janssens; Nina Wagner-Johnston; Oliver Ottmann; Jon Arnason; Hervé Tilly; Michael Millenson; Fritz Offner; Nashat Y Gabrail; Siddhartha Ganguly; Sikander Ailawadhi; Siddha Kasar; Arnon P Kater; Jeanette K Doorduijn; Lei Gao; Joanne J Lager; Bin Wu; Coumaran Egile; Marie José Kersten
Journal:  Lancet Haematol       Date:  2018-03-14       Impact factor: 18.959

Review 7.  Small Molecule Inhibitors in Chronic Lymphocytic Lymphoma and B Cell Non-Hodgkin Lymphoma.

Authors:  Allison Rosenthal
Journal:  Curr Hematol Malig Rep       Date:  2017-06       Impact factor: 3.952

Review 8.  Molecular Pathogenesis of Mantle Cell Lymphoma.

Authors:  Alba Navarro; Sílvia Beà; Pedro Jares; Elías Campo
Journal:  Hematol Oncol Clin North Am       Date:  2020-07-22       Impact factor: 3.722

Review 9.  Cell Cycle Dysregulation in Mantle Cell Lymphoma: Genomics and Therapy.

Authors:  Kevin Wang; Xiangao Huang; Maurizio Di Liberto; Selina Chen-Kiang
Journal:  Hematol Oncol Clin North Am       Date:  2020-08-01       Impact factor: 3.722

Review 10.  Status of PI3K/Akt/mTOR pathway inhibitors in lymphoma.

Authors:  Jason R Westin
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2014-02-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.